🇺🇸 FDA

Intelligence · Clinical Pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs
7,238

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Page 125 of 151

  1. TOCILIZUMAB , SECUKINUMAB , ANAKINRA , ADALIMUMAB , RITUXIMAB, USTEKINUMAB

    Pari Pharma GmbH

    Patients displaying a non-classified, severe and resistant inflammatory disease

    phase 2 small molecule active

    1 trial

  2. TOCILIZUMAB, FLUDARABINE PHOSPHATE, YTB323, CYCLOPHOSPHAMIDE

    Novartis Pharmaceuticals

    Relapsing Multiple Sclerosis

    phase 2 small molecule active

    1 trial

  3. TOCILIZUMAB, OBINUTUZUMAB, GLOFITAMAB, GLOFITAMAB

    Fondazione Telethon ETS

    Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  4. TOPIRAMATE

    Disc Medicine

    human immunodeficiency virus 1 (HIV-1)

    phase 2 small molecule active

    1 trial

  5. TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE, TEMOZOLOMIDE, TEMOZOLOMIDE, TEMOZOLOMIDE, TEMOZOLOMIDE, LEE011, TEMOZOLOMIDE, TEMOZOLOMIDE

    Novartis Pharmaceuticals

    Relapsed or refractory neuroblastoma and other solid tumors (including medulloblastoma, high grade glioma, malignant rhabdoid tumors, and rhabdomyosarcoma)

    phase 2 small molecule active

    1 trial

  6. TOPOTECANE ACCORD 1 mg/ml, solution à diluer pour perfusion, VINCRISTINE HOSPIRA 2 mg/2 ml, solution injectable, Etoposide 20 mg/ml concentrate for solution for infusion, CARBOPLATINE HOSPIRA 10 mg/ml, solution injectable pour perfusion, MELPHALAN TILLOMED 50 mg/10 mL, poudre et solvant pour solution injectable / pour perfusion, Topotecan Hospira 4 mg/4 ml concentrate for solution for infusion

    The George Institute

    Ocular conservative treatment for retinoblastoma

    phase 2 small molecule active

    1 trial

  7. TP-03

    Tarsus Pharmaceuticals

    Meibomian Gland Dysfunction

    phase 2 small molecule completed

    1 trial

  8. TP-05 (lotilaner) Low Dose

    Tarsus Pharmaceuticals

    Lyme Disease

    phase 2 small molecule active

    1 trial

  9. TP-38

    Teva Pharma GmbH

    Glioblastoma Multiforme

    phase 2 small molecule completed

    1 trial

  10. TP-38

    Teva Pharma GmbH

    Recurrent Glioblastoma Multiforme

    phase 2 small molecule completed

    1 trial

  11. TPC induction chemotherapy

    Sun Yat-sen University

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial

  12. TPIV200

    Marker Therapeutics

    Ovarian Cancer

    phase 2 mab completed

    1 trial

  13. TPM XR

    SUPERNUS PHARMACEUTICALS, INC.

    Epilepsy

    phase 2 small molecule completed

    1 trial

  14. TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Prostatic Neoplasms, Castration-Resistant

    phase 2 small molecule active

    1 trial

  15. TQB3616 capsules

    Chia Tai Tianqing Pharmaceutical Group Co.,

    HR-positive, HER2-negative Advanced Breast Cancer

    phase 2 small molecule completed

    1 trial

  16. TQC2731 injection

    Shanghai University of Traditional Chinese Medicine

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule active

    1 trial

  17. TQH2722 injection

    Shanghai University of Traditional Chinese Medicine

    Seasonal Allergic Rhinitis

    phase 2 small molecule active

    1 trial

  18. TRASTUZUMAB DERUXTECAN

    Fondazione Telethon ETS

    metastatic HER2-positive breast cancer patients

    phase 2 small molecule active

    1 trial

  19. TRASTUZUMAB DERUXTECAN, SACITUZUMAB GOVITECAN

    Ningbo Cancer Hospital

    Patients with metastatic or locally advanced HER2-low triple-negative breast cancer and eligible to receive sacituzumab-govitecan and T-Dxd according to their indication.

    phase 2 small molecule active

    1 trial

  20. TRASTUZUMAB EMTANSINE, Herceptin 150 mg powder for concentrate for solution for infusion, 89Zr-Trastuzumab_IJB

    The George Institute

    advanced/metastatic HER2-positive breast carcinoma

    phase 2 small molecule active

    1 trial

  21. TRASTUZUMAB, FULVESTRANT, EXEMESTANE, PERTUZUMAB, PERTUZUMAB, TRASTUZUMAB, PERTUZUMAB, TUKYSA 150 mg film-coated tablets, LETROZOLE, TUKYSA 50 mg film-coated tablets, TRASTUZUMAB, ANASTROZOLE

    Ningbo Cancer Hospital

    HER2+ metastatic breast cancer with isolated brain progression

    phase 2 small molecule active

    1 trial

  22. TRASTUZUMAB, TRASTUZUMAB, TRASTUZUMAB EMTANSINE, TRASTUZUMAB, TRASTUZUMAB DERUXTECAN, PERTUZUMAB, TRASTUZUMAB EMTANSINE

    Ningbo Cancer Hospital

    Patients with HER2-positive locally advanced inoperable or metastatic breast cancer with disease controlled after 2 years of maintenance treatment with anti-HER2 targeted therapy

    phase 2 small molecule active

    1 trial

  23. TRC105

    United Therapeutics Europe Ltd

    Metastatic Breast Cancer

    phase 2 small molecule completed

    1 trial

  24. TREDIMIN 25.000 U.I. /2,5 ml soluzione orale

    Sana Biotechnology

    haematologic condition who need staminal cells transplant

    phase 2 small molecule active

    1 trial

  25. TREMELIMUMAB, DURVALUMAB

    The George Institute

    MSS and MSI colorectal and endometrial tumors

    phase 2 small molecule active

    1 trial

  26. TREMELIMUMAB, Gemcitabina Accord 100 mg/ml concentrato per soluzione per infusione., CISPLATINO Pfizer 50 mg/50 ml soluzione per infusione, DURVALUMAB

    Fondazione Telethon ETS

    locally advanced cholangiocarcinoma

    phase 2 small molecule active

    1 trial

  27. TREPROSTINIL PALMITIL INHALATION POWDER, Placebo (inhalation powder capsules) containing 1 of 3 dosage strengths of TPIP (80 μg, 160 μg, or 320 μg), TREPROSTINIL PALMITIL INHALATION POWDER, TREPROSTINIL PALMITIL INHALATION POWDER

    Insmed Limited

    Pulmonary Arterial Hypertension

    phase 2 small molecule active

    1 trial

  28. TRETINOIN, gebasaxturev, MK-4280A, vibostolimab, MK-4830, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Stage IIIB or IIIC or IIID melanoma

    phase 2 small molecule active

    1 trial

  29. TRIPTORELIN, GONAPEPTYL 3,75 mg, poudre et solvant pour suspension injectable à libération prolongée en seringues pré-remplies., LEUPRORELIN ACETATE, BAY 1841788, TRIPTORELIN, DEGARELIX, LEUPRORELIN ACETATE, TRIPTORELIN, GOSERELIN ACETATE, LEUPRORELIN ACETATE, LEUPRORELIN ACETATE, TRIPTORELIN, GOSERELIN ACETATE, LEUPRORELIN ACETATE, DEGARELIX, LEUPRORELIN ACETATE

    The George Institute

    Adult patients with intermediate unfavorable risk prostate cancer as per NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines Prostate Cancer. Version 2.2021)

    phase 2 small molecule active

    1 trial

  30. TRU-016 and bendamustine

    Aptevo Therapeutics

    Chronic Lymphocytic Leukemia (CLL)

    phase 2 small molecule completed

    1 trial

  31. TRUQAP 200 mg film-coated tablets, TRUQAP 160 mg film-coated tablets

    AstraZeneca AB

    Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  32. TRV734

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-Use Disorder

    phase 2 small molecule completed

    1 trial

  33. TS-1 with cisplatin

    Hospital Authority, Hong Kong

    Recurrent Gastric Cancer

    phase 2 small molecule active

    1 trial

  34. TTI-101

    Tvardi Therapeutics

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule terminated

    1 trial

  35. TTI-101

    Tvardi Therapeutics

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule completed

    1 trial

  36. TTI-101

    Tvardi Therapeutics

    Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  37. TTP054

    vTv Therapeutics

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  38. TTP273

    vTv Therapeutics

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  39. TTP399

    vTv Therapeutics

    Diabetes Mellitus, Type 1

    phase 2 small molecule completed

    1 trial

  40. TTP399 400 mg

    vTv Therapeutics

    Diabetes Mellitus, Type 2

    phase 2 small molecule completed

    1 trial

  41. TTP435

    vTv Therapeutics

    Obesity

    phase 2 small molecule completed

    1 trial

  42. TTP889

    vTv Therapeutics

    Venous Thromboembolism

    phase 2 small molecule completed

    1 trial

  43. TTP889

    vTv Therapeutics

    Coagulation

    phase 2 small molecule terminated

    1 trial

  44. TTX-MC138

    Transcode Therapeutics

    Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  45. TUKYSA 50 mg film-coated tablets, TUKYSA 150 mg film-coated tablets

    Ningbo Cancer Hospital

    Non-resectable locally advanced or metastatic HER2-positive breast cancer

    phase 2 small molecule active

    1 trial

  46. TV-1380 150 mg

    Teva Pharma GmbH

    Cocaine Addiction

    phase 2 small molecule completed

    1 trial

  47. TV-45070

    Teva Pharma GmbH

    Osteoarthritis of the Knee

    phase 2 small molecule completed

    1 trial

  48. TV-45070

    Teva Pharma GmbH

    Postherpetic Neuralgia

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.